On February 7, 2020 NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare technology company, reported it has completed the sale of the company’s Connected Care assets to Masimo, a global leader in noninvasive monitoring technologies (NASDAQ: MASI) (Press release, NantHealth, FEB 7, 2020, View Source [SID1234554054]). The transaction follows the definitive agreement announced on January 14, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 7, 2020 UCLB spinout companies Odin Vision and Echopoint Medical reported that received awards at the 2019 SEHTA MedTech Business Awards on Thursday 6 February, alongside guest speaker Dr Eric Mayes, CEO, Endomag (Press release, UCLB, FEB 7, 2020, https://www.uclb.com/2020/02/07/two-uclb-spinout-companies-announced-winners-at-the-2019-sehta-medtech-business-awards/ [SID1234554050]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Echopoint Medical took home the Investment of the Year Award. This was for their achievements in receiving equity investment from UCL Technology Fund and Parkwalk Advisors, as well as significant InnovateUK grants to develop their technology. The spinout is developing optical sensing technology to help heart disease patients in a grey zone where the need for treatment is unclear.

Odin Vision, a spinout arising from the UCLB Portico Ventures Programme, took home the Start-Up Award and was named as a runner up in the Investment of the Year category. The AI start-up is using advanced computer vision and machine learning to help clinicians improve the detection and treatment of colorectal cancers during endoscopic procedures.

As winners of 2019 SEHTA MedTech Business Awards, both spinouts will be entered into the national Medilink UK Awards taking place on 1st April.

On February 7, 2020, Integra LifeSciences Holdings Corporation ("Integra") reported that it completed a private unregistered offering of $575 million aggregate principal amount of its 0.50% Convertible Notes due 2025 (the "Notes"), which amount includes the full exercise of the initial purchasers’ option to purchase additional Notes (Filing, 8-K, Integra LifeSciences, FEB 7, 2020, View Source [SID1234554049]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The net proceeds from this offering were approximately $558.4 million, after deducting the initial purchasers’ discounts and commissions and the estimated offering expenses payable by Integra. Integra used approximately $59.7 million of the net proceeds to pay the cost of the convertible note hedge transactions described below (after such cost was partially offset by the proceeds to Integra from the warrant transactions described below).

Integra used $100 million of the net proceeds from this offering to repurchase shares of Integra’s common stock, par value $0.01 per share ("Common Stock"), including approximately $7.6 million from certain purchasers of Notes in privately negotiated transactions effected through one of the initial purchasers as Integra’s agent concurrently with the completion of this offering and approximately $92.4 million through an accelerated share repurchase program, which Integra entered into with JPMorgan Chase Bank, National Association, New York branch on February 5, 2020, as described below. Integra expects to use the remainder of the net proceeds for general corporate purposes, which may include repayment of a portion of the indebtedness under Integra’s senior credit facility.

On February 7, 2020, Inovio Pharmaceuticals, Inc. (the "Company") reported that it entered into an amendment (the "Amendment") to the At-The-Market Equity Offering Sales Agreement dated May 25, 2018 (as amended, the "Sales Agreement") with Stifel, Nicolaus & Company, Incorporated ("Stifel"), which amendment increases the amount of Company common stock, par value $0.001 per share (the "Common Stock"), that can be sold by the Company through Stifel as its sales agent under the Sales Agreement from an aggregate offering price of up to $100,000,000 to an aggregate offering price of up to $200,000,000 (Filing, 8-K, Inovio, FEB 7, 2020, View Source [SID1234554048]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pursuant to the Sales Agreement, sales of the Common Stock, if any, will be made under the Company’s previously filed and effective Registration Statement on Form S-3 (File No. 333- 225233) and an applicable prospectus supplement, by any method that is deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended. Since September 30, 2019 the Company has sold approximately $68.3 million of its common stock pursuant to the Agreement and since May 25, 2018 has sold $100 million of its common stock pursuant to the Agreement.

The Sales Agreement is attached or incorporated by reference to this Current Report on Form 8-K as Exhibits 1.1 and 1.2 and is incorporated herein by reference. The foregoing description of the material terms of the Amendment does not purport to be complete and is qualified in its entirety by reference to the exhibits attached hereto.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

On February 7, 2020 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, reported its participation in the following upcoming investor conferences (Press release, Fate Therapeutics, FEB 7, 2020, View Source [SID1234554035]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Healthcare Talks | Oncology Day on Thursday, February 13, 2020 at 11:30 a.m. ET in New York, NY.
9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 3:30 p.m. ET in New York, NY.
Barclays Global Healthcare Conference on Thursday, March 12, 2020 at 8:30 a.m. ET in Miami, FL.
Oppenheimer’s 30th Annual Healthcare Conference on Wednesday, March 18, 2020 at 1:00 p.m. ET in New York, NY.
A live webcast of each presentation will be available through the investor relations section of the Company’s website at www.fatetherapeutics.com. Following each live webcast, an archived replay will be available on the Company’s website.